Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (111-120 of 302) with videos related to

Pageof 31
Sort By:
Leukemia & Lymphoma|August 28, 2010
Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisoneDavid Hui, Bradley Proctor, Jane Donaldson, et al.
British Journal of Haematology|February 13, 2003
Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypesDouglas E Horsman, Ichiro Okamoto, Olga Ludkovski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2003
Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials GroupC Tom Kouroukis, Andrew Belch, Michael Crump, et al.
Clinical Trials (London, England)|May 8, 2016
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial settingAjay K Gopal, Barbara Pro, Joseph M Connors, et al.
Haematologica|February 13, 2009
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failureNathalie A Johnson, Stephen Leach, Bruce Woolcock, et al.
Blood|January 25, 2007
Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community settingLaurie H Sehn, Jane Donaldson, Allison Filewich, et al.
Plos One|February 21, 2012
Genetic variation in cell death genes and risk of non-Hodgkin lymphomaJohanna M Schuetz, Denise Daley, Jinko Graham, et al.
Haematologica|October 3, 2009
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOPJesse Shustik, Guangming Han, Pedro Farinha, et al.
British Journal of Haematology|December 11, 2019
Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphomaAnna R Hayden, Derrick G Lee, Diego Villa, et al.
British Journal of Haematology|August 22, 2003
Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcomeValia S Lestou, Randy D Gascoyne, Laurie Sehn, et al.
Pageof 31

Showing results (111-120 of 302) with videos related to

Sort By:
Pageof 31
Leukemia & Lymphoma|August 28, 2010
Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisoneDavid Hui, Bradley Proctor, Jane Donaldson, et al.
British Journal of Haematology|February 13, 2003
Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypesDouglas E Horsman, Ichiro Okamoto, Olga Ludkovski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2003
Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials GroupC Tom Kouroukis, Andrew Belch, Michael Crump, et al.
Clinical Trials (London, England)|May 8, 2016
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial settingAjay K Gopal, Barbara Pro, Joseph M Connors, et al.
Haematologica|February 13, 2009
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failureNathalie A Johnson, Stephen Leach, Bruce Woolcock, et al.
Blood|January 25, 2007
Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community settingLaurie H Sehn, Jane Donaldson, Allison Filewich, et al.
Plos One|February 21, 2012
Genetic variation in cell death genes and risk of non-Hodgkin lymphomaJohanna M Schuetz, Denise Daley, Jinko Graham, et al.
Haematologica|October 3, 2009
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOPJesse Shustik, Guangming Han, Pedro Farinha, et al.
British Journal of Haematology|December 11, 2019
Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphomaAnna R Hayden, Derrick G Lee, Diego Villa, et al.
British Journal of Haematology|August 22, 2003
Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcomeValia S Lestou, Randy D Gascoyne, Laurie Sehn, et al.
Pageof 31